Fair Trade Commission Approves CG Inbites-Inbites Ecosystem Merger

CG Inbites announced on the 29th that it received approval for the corporate merger involving the incorporation into the Inbites ecosystem from the Fair Trade Commission on the 28th.

CG Inbites CI. [Image provided by CG Inbites]

The Fair Trade Commission completed its approval after reviewing whether the horizontal and vertical integration with the clinical trial outsourcing (CRO) business of Inbites BioCore, which is already part of the Inbites ecosystem, would restrict competition. This is because CG Inbites and its affiliates operate businesses related to pharmaceutical research and development, manufacturing, and CRO services.

As a result, the Inbites ecosystem has established a full-cycle value chain consisting of 10 bio and healthcare companies, including Inbites BioCore, HealthConnect, Inbites Genomics, ProCagen, and Inbites Ventures. With this merger approval, the legal procedures have also been completed.

After joining the Inbites ecosystem in June, CG Inbites changed its company name from the former Crystal Genomics to CG Inbites.

Meanwhile, the Inbites ecosystem is pursuing its business with the goal of implementing personalized health management and precision medical services based on data and technology.